Profile data is unavailable for this security.
About the company
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
- Revenue in EUR (TTM)13.12m
- Net income in EUR-83.97m
- Incorporated2002
- Employees106.00
- LocationDbv Technologies SABatiment IRO, 107 Av. de la RepubliqueCHATILLON 92320FranceFRA
- Phone+33 155427878
- Fax+33 143261083
- Websitehttps://www.dbv-technologies.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valerio Therapeutics SA | 1.89m | -19.66m | 12.35m | 38.00 | -- | 3.06 | -- | 6.54 | -0.1233 | -0.1233 | 0.0119 | 0.0261 | 0.0515 | -- | 0.5121 | 99,421.05 | -53.59 | -34.19 | -76.22 | -40.59 | 74.75 | 84.11 | -1,040.66 | -586.99 | -- | -188.64 | 0.7662 | -- | 24.74 | -21.73 | -4.00 | -- | 32.39 | -- |
| SMAIO SA | 4.91m | -1.79m | 14.17m | 43.00 | -- | 1.76 | -- | 2.88 | -0.3383 | -0.3383 | 0.929 | 1.54 | 0.3738 | 0.3816 | 9.41 | 132,756.80 | -13.65 | -7.87 | -15.68 | -18.43 | 88.45 | 96.04 | -36.52 | -22.48 | 4.25 | -- | 0.236 | -- | 212.18 | 114.99 | -62.80 | -- | -- | -- |
| NicOx SA | -100.00bn | -100.00bn | 15.74m | 5.00 | -- | 0.7203 | -- | -- | -- | -- | -- | 0.3166 | -- | -- | -- | -- | -- | -22.59 | -- | -24.55 | -- | -- | -- | -337.85 | -- | -- | 0.5424 | -- | 26.59 | 11.38 | 33.26 | -- | -- | -- |
| Advicenne SA | 3.02m | -8.83m | 26.00m | 20.00 | -- | -- | -- | 8.61 | -0.7538 | -0.7538 | 0.2608 | -1.42 | 0.3234 | 3.85 | 1.87 | 150,950.00 | -94.59 | -57.86 | -- | -89.10 | -116.10 | -327.56 | -292.51 | -513.56 | 0.2611 | -22.23 | 156.51 | -- | 25.67 | 25.03 | 38.70 | -- | 55.28 | -- |
| Aelis Farma SA | 7.55m | -7.03m | 41.12m | 26.00 | -- | 4.00 | -- | 5.44 | -0.5319 | -0.5319 | 0.5717 | 0.75 | 0.2779 | -- | 1.56 | 290,461.50 | -25.85 | -24.53 | -40.55 | -40.55 | -- | -- | -93.03 | -109.62 | 2.97 | -- | 0.277 | -- | 137.70 | -- | 64.46 | -- | 37.35 | -- |
| AB Science SA | 1.08m | -6.04m | 51.53m | 45.00 | -- | -- | -- | 47.62 | -0.1204 | -0.1204 | 0.0213 | -0.4697 | 0.0385 | 0.6465 | 6.98 | 20,415.09 | -21.51 | -65.95 | -70.06 | -515.17 | 76.25 | 88.41 | -558.50 | -1,148.98 | 0.798 | -9.11 | -- | -- | 1.25 | -10.63 | 11.97 | -- | -6.55 | -- |
| Groupe Berkem SA | 52.43m | -1.42m | 54.37m | 200.00 | -- | -- | 15.99 | 1.04 | -0.0799 | -0.0799 | 2.95 | -- | -- | -- | -- | 262,130.00 | -- | -- | -- | -- | 56.41 | -- | -2.71 | -- | -- | 0.1565 | -- | -- | 0.733 | -- | 123.42 | -- | -- | -- |
| DBV Technologies SA | 13.12m | -83.97m | 60.02m | 106.00 | -- | 0.7963 | -- | 4.58 | -0.8733 | -0.8733 | 0.1365 | 0.781 | 0.0833 | -- | 0.7321 | 126,141.70 | -53.33 | -53.18 | -65.29 | -65.47 | -- | 93.62 | -640.08 | -1,145.92 | -- | -- | 0.083 | -- | 224.69 | -1.71 | 24.27 | -- | -34.47 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Braidwell LPas of 30 Oct 2024 | 230.85k | 0.24% |
| UBS LA MAISON de Gestionas of 30 Dec 2022 | 100.00k | 0.10% |
| La Fran�aise Asset Management SASas of 31 Jul 2024 | 55.00k | 0.06% |
| HSBC Global Asset Management (France) SAas of 30 Sep 2024 | 14.85k | 0.02% |
| Dimensional Fund Advisors LPas of 31 Jul 2024 | 3.20k | 0.00% |
| SSgA Funds Management, Inc.as of 03 Oct 2024 | 2.58k | 0.00% |
| American Century Investment Management, Inc.as of 03 Oct 2024 | 421.00 | 0.00% |
| DWS Investment GmbHas of 31 Dec 2022 | 0.00 | 0.00% |
